Mircea Ivan, M.D., Ph.D.
980 W. Walnut St.
Indianapolis, IN 46202
Phone: (317) 274-0322
Fax: (317) 274-3096
Research Program Membership
Department of Medicine
Division of Hematology/Oncology
IU School of Medicine
Department of Microbiology and Immunology
Hypoxia is a major component of the tumor microenvironment, and exhibits a negative impact on the outcome of cancer therapy. Detailed understanding of the mechanisms of cellular adaptation to low oxygen is anticipated to result in important therapeutic applications for breast cancer. 1. We aim to understand the role of specific microRNAs in the hypoxia response and in the progression of breast cancer. The current focus is on miR-210. We have demonstrated (and other groups subsequently confirmed) that miR-210 is a direct target of Hypoxia Inducible Factors (HIFs), master regulators of the response to low oxygen, with critical roles in tumor formation. Importantly, miR-210 was found by multiple studies to be overexpressed in most solid cancers, and its upregulation was recently associated with adverse prognosis. We aim to mechanistically dissect the role of miR-210 in metabolism and cell survival by identifying critical targets. We are also developing novel animal models of cancer with altered level of miR-210. Another focus of the group is to expand on our knowledge of Hypoxia-regulated noncoding RNAs beyond the microRNA world. My laboratory is funded by the American Cancer Society and the National Cancer Institute.
Post-doctoral Fellowship - Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 1998-2002
Ph.D. - Cardiff University School of Medicine, United Kingdom 1994-1998
M.D. - Carol Davila University of Medicine and Pharmacy, Bucharest, Romania 1987-1993